It has long been known that these agents, particularly the tumor necrosis factor-alpha (TNFα) inhibitors such as Infliximab, put patients at increased risk for opportunistic infections and reactivation of latent infections such as tuberculosis. Here, TNF is linked to disease arising from reactivation of latent virus.